Pfizer Ltd
NSE:PFIZER
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 031.9
6 318.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pfizer Ltd
Pfizer Ltd
Gross Profit
Pfizer Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pfizer Ltd
NSE:PFIZER
|
Gross Profit
₹14.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Gross Profit
₹205B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Gross Profit
₹177.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Gross Profit
₹398.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Gross Profit
₹84.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Gross Profit
₹69.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Ltd
Glance View
Pfizer Ltd. engages in the business of manufacturing, marketing, trading, import and export of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 2,285 full-time employees. The firm has a portfolio of approximately 150 products across over 15 therapeutic areas. The firm is engaged in manufacturing, marketing, trading and exporting pharmaceutical products. The firm offers a range of products for anti-diabetic, anti-infectives, cardiovascular, dermatology, erectile dysfunction, gastrointestinal (GI), multivitamins, neurology, pain/fever/inflammation and autoimmune disorders, among others. Its products include Trulimax, Vibazime DT, Viagra, Daxid, Tricorex, Mucaine, Diamox, Hetrazan, Enbrel, Ativan, Pacitane, Folvite Tablets, Autrin Capsules, Prevenar 13, Wysolone, Loette, Ovral G, Ovral L, Premarin tablets, Premarin Vaginal Cream, Zosyn, Wymox, Tygacil, Cynomycin, Targit, Cyklokapron and Magnamycin. The firm has its own manufacturing facility at Thane and Goa. The firm has various independent contract/third party manufacturers based across the country.
See Also
What is Pfizer Ltd's Gross Profit?
Gross Profit
14.5B
INR
Based on the financial report for Sep 30, 2024, Pfizer Ltd's Gross Profit amounts to 14.5B INR.
What is Pfizer Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
7%
Over the last year, the Gross Profit growth was 1%. The average annual Gross Profit growth rates for Pfizer Ltd have been -3% over the past three years , 1% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
